{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:39:42Z","timestamp":1788813582207,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12234-7","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:34:54Z","timestamp":1782563694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond minimum inhibitory concentration values: clinical and diagnostic challenges of colistin heteroresistance in Acinetobacter baumannii"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-5847","authenticated-orcid":false,"given":"Esra","family":"Ta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8147-1028","authenticated-orcid":false,"given":"Feride Mehtap","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"12234_CR1","doi-asserted-by":"publisher","first-page":"107605","DOI":"10.1016\/j.micpath.2025.107605","volume":"204","author":"R Sharma","year":"2025","unstructured":"Sharma R, Lakhanpal D (2025) Acinetobacter baumannii: A comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies. Microb Pathog 204:107605. https:\/\/doi.org\/10.1016\/j.micpath.2025.107605","journal-title":"Microb Pathog"},{"issue":"12","key":"12234_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nrmicro1789","volume":"5","author":"L Dijkshoorn","year":"2007","unstructured":"Dijkshoorn L, Nemec A, Seifert H (2007) An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5(12):939\u2013951. https:\/\/doi.org\/10.1038\/nrmicro1789","journal-title":"Nat Rev Microbiol"},{"issue":"4\u20135","key":"12234_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drup.2010.05.002","volume":"13","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Rafailidis PI, Matthaiou DK (2010) Resistance to polymyxins: mechanisms, frequency and treatment options. Drug resistance updates\u202f: reviews and commentaries in antimicrobial and anticancer chemotherapy 13(4\u20135):132\u2013138. https:\/\/doi.org\/10.1016\/j.drup.2010.05.002","journal-title":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"issue":"8","key":"12234_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","volume":"25","author":"E-T Piperaki","year":"2019","unstructured":"Piperaki E-T, Tzouvelekis LS, Miriagou V, Daikos GL (2019) Carbapenem-resistant Acinetobacter baumannii: In pursuit of an effective treatment. Clin Microbiol Infect 25(8):951\u2013957. https:\/\/doi.org\/10.1016\/j.cmi.2019.03.014","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"12234_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1179\/1973947814Y.0000000213","volume":"28","author":"CH Rodr\u00edguez","year":"2016","unstructured":"Rodr\u00edguez CH, Nastro M, Fiorilli G, Dabos L, Lopez Calvo J, Fari\u00f1a ME, Vay C, Famiglietti A (2016) Trends in the resistance profiles of Acinetobacter baumannii endemic clones in a university hospital of Argentina. J Chemother 28(1):25\u201327. https:\/\/doi.org\/10.1179\/1973947814Y.0000000213","journal-title":"J Chemother"},{"issue":"2","key":"12234_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/1040841X.2020.1863329","volume":"47","author":"SP Lopes","year":"2021","unstructured":"Lopes SP, Jorge P, Sousa AM, Pereira MO (2021) Discerning the role of polymicrobial biofilms in the ascent, prevalence, and extent of heteroresistance in clinical practice. Crit Rev Microbiol 47(2):162\u2013191","journal-title":"Crit Rev Microbiol"},{"issue":"2","key":"12234_CR7","doi-asserted-by":"publisher","first-page":"106065","DOI":"10.1016\/j.ijantimicag.2020.106065","volume":"56","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis S, Saridakis I (2020) Colistin heteroresistance in Acinetobacter spp.: Systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents 56(2):106065. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106065","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"12234_CR8","doi-asserted-by":"publisher","first-page":"e02448","DOI":"10.1128\/mBio.02448-17","volume":"9","author":"VI Band","year":"2018","unstructured":"Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS (2018) Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. mBio 9(1):e02448\u2013e02417. https:\/\/doi.org\/10.1128\/mBio.02448-17","journal-title":"mBio"},{"issue":"2","key":"12234_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2009.07.005","volume":"65","author":"RC Hernan","year":"2009","unstructured":"Hernan RC, Karina B, Gabriela G, Marcela N, Carlos V, Angela F (2009) Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 65(2):188\u2013191. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.07.005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"12234_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International journal of surgery (London, England) 88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906","journal-title":"International journal of surgery (London, England)"},{"key":"12234_CR11","first-page":"457","volume":"3","author":"Y Koyama","year":"1950","unstructured":"Koyama Y (1950) A new antibiotic \u201ccolistin\u201d produced by spore-forming soil bacteria. J Antibiot 3:457\u2013458","journal-title":"J Antibiot"},{"issue":"9","key":"12234_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK (2005) Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333\u20131341","journal-title":"Clin Infect Dis"},{"issue":"4","key":"12234_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1185\/03007995.2015.1018989","volume":"31","author":"AZ Bialvaei","year":"2015","unstructured":"Bialvaei AZ, Samadi Kafil H (2015) Colistin: Mechanisms and prevalence of resistance. Curr Med Res Opin 31(4):707\u2013721","journal-title":"Curr Med Res Opin"},{"key":"12234_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jgar.2019.01.028","volume":"18","author":"A El-Nawawy","year":"2019","unstructured":"El-Nawawy A, Ramadan M-F, Antonios M-M, Arafa S-F, Hamza E (2019) Bacteriologic profile and susceptibility pattern of mechanically ventilated paediatric patients with pneumonia. J Glob Antimicrob Resist 18:88\u201394","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"12234_CR15","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1128\/AAC.00103-06","volume":"50","author":"J Li","year":"2006","unstructured":"Li J, Rayner CR, Nation RL et al (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50(9):2946\u20132950","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"12234_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1111\/jcpt.13787","volume":"47","author":"R Dehbanipour","year":"2022","unstructured":"Dehbanipour R, Ghalavand Z (2022) Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline. J Clin Pharm Ther 47(12):1875\u20131884","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"12234_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1\u201312","journal-title":"Clin Infect Dis"},{"key":"12234_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12941-021-00480-5","volume":"20","author":"N Yousefi Nojookambari","year":"2021","unstructured":"Yousefi Nojookambari N, Sadredinamin M, Dehbanipour R et al (2021) Prevalence of \u03b2-lactamase-encoding genes and molecular typing of Acinetobacter baumannii isolates carrying carbapenemase OXA-24 in children. Ann Clin Microbiol Antimicrob 20:75","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"12234_CR19","unstructured":"European Centre for Disease Prevention and Control (2019) Surveillance of antimicrobial resistance in Europe 2018. ECDC"},{"key":"12234_CR20","first-page":"73","volume":"142","author":"P Hejnar","year":"1999","unstructured":"Hejnar P, Kol\u00e1\u0159 M, H\u00e1jek V (1999) Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Universitatis Palackianae Olomucensis Facultatis Medicae 142:73\u201377","journal-title":"Acta Universitatis Palackianae Olomucensis Facultatis Medicae"},{"issue":"6","key":"12234_CR21","doi-asserted-by":"publisher","first-page":"16053","DOI":"10.1038\/nmicrobiol.2016.53","volume":"1","author":"VI Band","year":"2016","unstructured":"Band VI, Crispell EK, Napier BA, Herrera CM, Tharp GK, Vavikolanu K, Pohl J, Read TD, Bosinger SE, Trent MS, Burd EM, Weiss DS (2016) Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol 1(6):16053. https:\/\/doi.org\/10.1038\/nmicrobiol.2016.53","journal-title":"Nat Microbiol"},{"issue":"3","key":"12234_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2012.04.002","volume":"73","author":"AM Queenan","year":"2012","unstructured":"Queenan AM, Pillar CM, Deane J et al (2012) Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 73(3):267\u2013270","journal-title":"Diagn Microbiol Infect Dis"},{"key":"12234_CR23","doi-asserted-by":"publisher","first-page":"103887","DOI":"10.1016\/j.micpath.2019.103887","volume":"139","author":"A Pormohammad","year":"2020","unstructured":"Pormohammad A, Mehdinejadiani K, Gholizadeh P et al (2020) Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microb Pathog 139:103887","journal-title":"Microb Pathog"},{"issue":"3","key":"12234_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/jac\/dkm504","volume":"61","author":"MJ Matteo","year":"2008","unstructured":"Matteo MJ, Granados G, Olmos M, Wonaga A, Catalano M (2008) Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J Antimicrob Chemother 61(3):474\u2013477. https:\/\/doi.org\/10.1093\/jac\/dkm504","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"12234_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1183\/09031936.00089808","volume":"33","author":"S Hofmann-Thiel","year":"2009","unstructured":"Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H (2009) Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33(2):368\u2013374. https:\/\/doi.org\/10.1183\/09031936.00089808","journal-title":"Eur Respir J"},{"issue":"12","key":"12234_CR26","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1128\/JCM.01602-13","volume":"51","author":"DB Folkvardsen","year":"2013","unstructured":"Folkvardsen DB, Thomsen V\u00d8, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E (2013) Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol 51(12):4220\u20134222. https:\/\/doi.org\/10.1128\/JCM.01602-13","journal-title":"J Clin Microbiol"},{"issue":"8","key":"12234_CR27","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.02820-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ (2014) Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 58(8):4636\u20134641. https:\/\/doi.org\/10.1128\/AAC.02820-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"12234_CR28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10096-017-3044-2","volume":"36","author":"CK Kang","year":"2017","unstructured":"Kang CK, Kim YK, Jung SI, Park WB, Song KH, Park KH, Choe PG, Jang HC, Lee S, Kim YS, Kwak YG, Kwon KT, Kiem S, Kim CJ, Kim ES, Kim HB, Korea INfectious Diseases (KIND) study group (2017) agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol 36(11):2187\u20132191. https:\/\/doi.org\/10.1007\/s10096-017-3044-2","journal-title":"Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol"},{"issue":"1","key":"12234_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","volume":"28","author":"OM El-Halfawy","year":"2015","unstructured":"El-Halfawy OM, Valvano MA (2015) Antimicrobial heteroresistance: An emerging field in need of clarity. Clin Microbiol Rev 28(1):191\u2013207. https:\/\/doi.org\/10.1128\/CMR.00058-14","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"12234_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","volume":"17","author":"DI Andersson","year":"2019","unstructured":"Andersson DI, Nicoloff H, Hjort K (2019) Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol 17(8):479\u2013496. https:\/\/doi.org\/10.1038\/s41579-019-0218-1","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"12234_CR31","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1080\/22221751.2020.1821584","volume":"9","author":"Y-K Hong","year":"2020","unstructured":"Hong Y-K, Kim H, Ko KS (2020) Two types of colistin heteroresistance in Acinetobacter baumannii isolates. Emerg Microbes Infections 9(1):2114\u20132123","journal-title":"Emerg Microbes Infections"},{"issue":"1","key":"12234_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/AAC.00766-07","volume":"52","author":"JS Hawley","year":"2008","unstructured":"Hawley JS, Murray CK, Jorgensen JH (2008) Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52(1):351\u2013352","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"12234_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jinf.2008.11.002","volume":"58","author":"W Yau","year":"2009","unstructured":"Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, Nation RL, Li J (2009) Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58(2):138\u2013144. https:\/\/doi.org\/10.1016\/j.jinf.2008.11.002","journal-title":"J Infect"},{"issue":"9","key":"12234_CR34","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/jac\/dkq226","volume":"65","author":"RV Dudhani","year":"2010","unstructured":"Dudhani RV, Turnidge JD, Nation RL, Li J (2010) fAUC\/MIC is the most predictive pharmacokinetic\/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65(9):1984\u20131990","journal-title":"J Antimicrob Chemother"},{"key":"12234_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3855\/jidc.604","volume":"4","author":"CH Rodriguez","year":"2010","unstructured":"Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, Radice M, Gutkind G, Vay C, Famiglietti A (2010) In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 4:164\u2013167. https:\/\/doi.org\/10.3855\/jidc.604","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"12234_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1590\/S0325-75412011000200009","volume":"43","author":"ME Herrera","year":"2011","unstructured":"Herrera ME, Mobilia LN, Posse GR (2011) Sensibilidad de Acinetobacter a la colistina evaluada mediante los m\u00e9todos de predifusi\u00f3n y de concentraci\u00f3n inhibitoria m\u00ednima: Detecci\u00f3n de aislamientos heterorresistentes [Comparative evaluation of the sensitivity of Acinetobacter to colistin, using the prediffusion and minimum inhibitory concentration methods: detection of heteroresistant isolates]. Rev Argent Microbiol 43(2):115\u2013119. https:\/\/doi.org\/10.1590\/S0325-75412011000200009","journal-title":"Rev Argent Microbiol"},{"issue":"9","key":"12234_CR37","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.05996-11","volume":"56","author":"C Vidaillac","year":"2012","unstructured":"Vidaillac C, Benichou L, Duval RE (2012) In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56(9):4856\u20134861. https:\/\/doi.org\/10.1128\/AAC.05996-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"12234_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1179\/1973947814Y.0000000213","volume":"28","author":"CH Rodr\u00edguez","year":"2016","unstructured":"Rodr\u00edguez CH, Nastro M, Fiorilli G, Dabos L, Lopez Calvo J, Fari\u00f1a ME, Vay C, Famiglietti A (2016) Trends in the resistance profiles of Acinetobacter baumannii endemic clones in a university hospital of Argentina. J Chemother 28(1):25\u201327. https:\/\/doi.org\/10.1179\/1973947814Y.0000000213","journal-title":"J Chemother"},{"key":"12234_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jgar.2017.08.002","volume":"11","author":"E Juh\u00e1sz","year":"2017","unstructured":"Juh\u00e1sz E, Iv\u00e1n M, Pint\u00e9r E, Pongr\u00e1cz J, Krist\u00f3f K (2017) Colistin resistance among blood culture isolates at a tertiary care centre in Hungary. J Glob Antimicrob Resist 11:167\u2013170","journal-title":"J Glob Antimicrob Resist"},{"key":"12234_CR40","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.55956","volume":"10","author":"H Li","year":"2017","unstructured":"Li H, Zhou H, Li X, Wang J, Fu Y, Jiang Y, Yu Y (2017) The evaluation of four in vitro susceptibility testing methods for colistin on carbapenem-resistant Acinetobacter baumannii. Jundishapur J Microbiol 10:e55956","journal-title":"Jundishapur J Microbiol"},{"issue":"2","key":"12234_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2018.01.028","volume":"91","author":"P Srinivas","year":"2018","unstructured":"Srinivas P, Hunt LN, Pouch SM, Thomas K, Goff DA, Pancholi P, Balada-Llasat J-M, Bauer KA (2018) Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates. Diagn Microbiol Infect Dis 91(2):194\u2013198. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.01.028","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"12234_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ijantimicag.2019.08.010","volume":"54","author":"CH Rodriguez","year":"2019","unstructured":"Rodriguez CH, Traglia G, Bastias N, Pandolfo C, Bruni G, Nastro M, Barrios R, Bavastro EM, Rey MC, Marques IA, Heger F, Vay C, Fernandez JS, Ramirez MS, Famiglietti A (2019) Discrepancies in susceptibility testing to colistin in Acinetobacter baumannii: The influence of slow growth and heteroresistance. Int J Antimicrob Agents 54(5):587\u2013591. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.010","journal-title":"Int J Antimicrob Agents"},{"key":"12234_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jgar.2019.11.010","volume":"21","author":"F Ezadi","year":"2020","unstructured":"Ezadi F, Jamali A, Heidari A, Javid N, Ardebili A (2020) Heteroresistance to colistin in oxacillinase-producing carbapenem-resistant Acinetobacter baumannii clinical isolates from Gorgan, Northern Iran. J Glob Antimicrob Resist 21:380\u2013385. https:\/\/doi.org\/10.1016\/j.jgar.2019.11.010","journal-title":"J Glob Antimicrob Resist"},{"key":"12234_CR44","doi-asserted-by":"publisher","unstructured":"\u00c7a\u011flan E, Nigiz \u015e, Sancak B, G\u00fcr D (2019) Resistance and heteroresistance to colistin among clinical isolates of Acinetobacter baumannii. Acta Microbiol Immunol Hung 111. https:\/\/doi.org\/10.1556\/030.66.2019.021","DOI":"10.1556\/030.66.2019.021"},{"issue":"7","key":"12234_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41429-020-0289-2","volume":"73","author":"L Chen","year":"2020","unstructured":"Chen L, Lin J, Lu H et al (2020) Deciphering colistin heteroresistance in Acinetobacter baumannii clinical isolates from Wenzhou, China. J Antibiot 73(7):463\u2013470. https:\/\/doi.org\/10.1038\/s41429-020-0289-2","journal-title":"J Antibiot"},{"issue":"1","key":"12234_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10010048","volume":"10","author":"F Sacco","year":"2021","unstructured":"Sacco F, Visca P, Runci F, Antonelli G, Raponi G (2021) Susceptibility Testing of Colistin for Acinetobacter baumannii: How Far Are We from the Truth? Antibiotics 10(1):48. https:\/\/doi.org\/10.3390\/antibiotics10010048","journal-title":"Antibiotics"},{"key":"12234_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00914-6","volume":"30","author":"J Jo","year":"2023","unstructured":"Jo J, Kwon KT, Ko KS (2023) Multiple heteroresistance to tigecycline and colistin in Acinetobacter baumannii isolates and its implications for combined antibiotic treatment. J Biomed Sci 30:37. https:\/\/doi.org\/10.1186\/s12929-023-00914-6","journal-title":"J Biomed Sci"},{"key":"12234_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05093-22","volume":"11","author":"H Kon","year":"2023","unstructured":"Kon H, Hameir A, Nutman A, Temkin E, Keren Paz A, Lellouche J, Schwartz D, Weiss DS, Kaye KS, Daikos GL, Skiada A, Durante-Mangoni E, Dishon Benattar Y, Yahav D, Daitch V, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Dickstein Y, Pollak D, Mendelsohn S, Paul M, Carmeli Y (2023) Prevalence and clinical consequences of colistin heteroresistance and evolution into full resistance in carbapenem-resistant Acinetobacter baumannii. Microbiol Spectr 11:e05093-22. https:\/\/doi.org\/10.1128\/spectrum.05093-22","journal-title":"Microbiol Spectr"},{"issue":"1","key":"12234_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10096-024-04988-4","volume":"44","author":"A Zulfiqar","year":"2025","unstructured":"Zulfiqar A, Hanif F, Irfan R, Qasim A, Usman J (2025) Incidence of colistin heteroresistance among carbapenem-resistant Acinetobacter baumannii clinical isolates in a tertiary care hospital in Pakistan. Eur J Clin Microbiol Infect Dis 44(1):151\u2013158. https:\/\/doi.org\/10.1007\/s10096-024-04988-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"12234_CR50","doi-asserted-by":"publisher","DOI":"10.2174\/0115701638253395230919112548","volume":"21","author":"I Pakzad","year":"2024","unstructured":"Pakzad I, Yarkarami F, Kalani BS, Shafieian M, Hematian A (2024) Inhibitory Effects of Carvacrol on Biofilm Formation in Colistin Heteroresistant Acinetobacter baumannii Clinical Isolates. Curr Drug Discov Technol 21(1):e280923221542. https:\/\/doi.org\/10.2174\/0115701638253395230919112548","journal-title":"Curr Drug Discov Technol"},{"key":"12234_CR51","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.nmni.2025.101633","volume":"67","author":"A Hematian","year":"2025","unstructured":"Hematian A, Karami-Zarandi M, Rahdar HA, Heidari H, Kazemian H (2025) Investigation of colistin heteroresistance in multidrug-resistant Acinetobacter baumannii clinical isolates. New Microbes New Infections 67:101633. https:\/\/doi.org\/10.1016\/j.nmni.2025.101633","journal-title":"New Microbes New Infections"},{"issue":"4","key":"12234_CR52","doi-asserted-by":"publisher","first-page":"dkag076","DOI":"10.1093\/jac\/dkag076","volume":"81","author":"B Sancak","year":"2026","unstructured":"Sancak B, K\u0131rba\u015f E, Ari O, Durmaz R (2026) Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity. J Antimicrob Chemother 81(4):dkag076. https:\/\/doi.org\/10.1093\/jac\/dkag076","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"12234_CR53","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1128\/AAC.00834-10","volume":"54","author":"JH Moffatt","year":"2010","unstructured":"Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, Michael S, Cox F, Adler AD, Nation B, Li RL, J., Boyce JD (2010) Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54(12):4971\u20134977. https:\/\/doi.org\/10.1128\/AAC.00834-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"12234_CR54","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s10096-016-2736-3","volume":"35","author":"H Nordqvist","year":"2016","unstructured":"Nordqvist H, Nilsson LE, Claesson C (2016) Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 35(11):1845\u20131850. https:\/\/doi.org\/10.1007\/s10096-016-2736-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"12234_CR55","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1128\/AAC.00284-09","volume":"53","author":"MD Adams","year":"2009","unstructured":"Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA (2009) Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53(9):3628\u20133634. https:\/\/doi.org\/10.1128\/AAC.00284-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"12234_CR56","doi-asserted-by":"publisher","first-page":"e02511","DOI":"10.1128\/spectrum.02511-23","volume":"12","author":"S Vijayakumar","year":"2024","unstructured":"Vijayakumar S, Swetha RG, Bakthavatchalam YD, Vasudevan K, Shankar BA, Kirubananthan A, Walia K, Ramaiah S, Biswas I, Veeraraghavan B, Anbarasu A (2024) Genomic investigation unveils colistin resistance mechanism in carbapenem-resistant Acinetobacter baumannii clinical isolates. Microbiol Spectr 12(2):e02511\u2013e02523. https:\/\/doi.org\/10.1128\/spectrum.02511-23","journal-title":"Microbiol Spectr"},{"issue":"6","key":"12234_CR57","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1099\/jmm.0.000741","volume":"67","author":"D Machado","year":"2018","unstructured":"Machado D, Antunes J, Sim\u00f5es A, Perdig\u00e3o J, Couto I, McCusker M, Martins M, Portugal I, Pacheco T, Batista J, Toscano C, Viveiros M (2018) Contribution of efflux to colistin heteroresistance in a multidrug-resistant Acinetobacter baumannii clinical isolate. J Med Microbiol 67(6):740\u2013749. https:\/\/doi.org\/10.1099\/jmm.0.000741","journal-title":"J Med Microbiol"},{"issue":"6","key":"12234_CR58","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.85.6.607","volume":"85","author":"HE Alexander","year":"1947","unstructured":"Alexander HE, Leidy G (1947) Mode of action of streptomycin on type b Haemophilus influenzae. II. Nature of resistant variants. J Exp Med 85(6):607\u2013621","journal-title":"J Exp Med"},{"issue":"10","key":"12234_CR59","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1128\/AAC.01406-06","volume":"51","author":"JR Lo-Ten-Foe","year":"2007","unstructured":"Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen PH (2007) Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrobial agents and chemotherapy 51(10):3726\u20133730. https:\/\/doi.org\/10.1128\/AAC.01406-06","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"12234_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9118-1_4","author":"EX Sherman","year":"2019","unstructured":"Sherman EX, Wozniak JE, Weiss DS (2019) Methods to evaluate colistin heteroresistance in Acinetobacter baumannii. Acinetobacter baumannii. https:\/\/doi.org\/10.1007\/978-1-4939-9118-1_4","journal-title":"Acinetobacter baumannii"},{"issue":"1","key":"12234_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01390-18","volume":"57","author":"FA Ezadi","year":"2019","unstructured":"Ezadi FA, Ardebili A, Mirnejad R (2019) Antimicrobial susceptibility testing for polymyxins: challenges, issues, and recommendations. Journal of Clinical Microbiology 57(1):e01390-18. https:\/\/doi.org\/10.1128\/JCM.01390-18","journal-title":"Journal of Clinical Microbiology"},{"issue":"2","key":"12234_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.molcel.2019.09.028","volume":"76","author":"L Dewachter","year":"2019","unstructured":"Dewachter L, Fauvart M, Michiels J (2019) Bacterial heterogeneity and antibiotic survival: understanding and combatting persistence and heteroresistance. Molecular Cell 76(2):255\u2013267. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.028","journal-title":"Molecular Cell"},{"issue":"10","key":"12234_CR63","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","volume":"4","author":"VI Band","year":"2019","unstructured":"Band VI, Hufnagel DA, Jaggavarapu S, Sherman EX, Wozniak JE, Satola SW, Farley MM, Jacob JT, Burd EM, Weiss DS (2019) Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nature Microbiology 4(10):1627\u20131635. https:\/\/doi.org\/10.1038\/s41564-019-0480-z","journal-title":"Nature Microbiology"},{"issue":"1","key":"12234_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12929-023-00914-6","volume":"30","author":"J Jo","year":"2023","unstructured":"Jo J, Kwon KT, Ko KS (2023) Multiple heteroresistance to tigecycline and colistin in Acinetobacter baumannii isolates and its implications for combined antibiotic treatment. Journal of Biomedical Science 30(1):37. https:\/\/doi.org\/10.1186\/s12929-023-00914-6","journal-title":"Journal of Biomedical Science"},{"issue":"3","key":"12234_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150642","volume":"11","author":"WY Kim","year":"2016","unstructured":"Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB (2016) Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS ONE 11(3):e0150642. https:\/\/doi.org\/10.1371\/journal.pone.0150642","journal-title":"PLoS ONE"},{"issue":"7","key":"12234_CR66","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3109\/23744235.2016.1155735","volume":"48","author":"Y Cai","year":"2016","unstructured":"Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R (2016) Tigecycline: alone or in combination? Infectious Diseases 48(7):491\u2013502. https:\/\/doi.org\/10.3109\/23744235.2016.1155735","journal-title":"Infectious Diseases"},{"key":"12234_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90732-3","volume":"11","author":"Y Sato","year":"2021","unstructured":"Sato Y, Ubagai T, Tansho-Nagakawa S, Yoshino Y, Ono Y (2021) Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination. Scientific Reports 11:11700. https:\/\/doi.org\/10.1038\/s41598-021-90732-3","journal-title":"Scientific Reports"},{"key":"12234_CR68","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"J Liu","year":"2021","unstructured":"Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L, Wang G (2021) Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J global Antimicrob Resist 24:136\u2013147. https:\/\/doi.org\/10.1016\/j.jgar.2020.08.021","journal-title":"J global Antimicrob Resist"},{"issue":"7","key":"12234_CR69","doi-asserted-by":"publisher","first-page":"e0270908","DOI":"10.1371\/journal.pone.0270908","volume":"17","author":"MM Almutairi","year":"2022","unstructured":"Almutairi MM (2022) Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates. PLoS ONE 17(7):e0270908. https:\/\/doi.org\/10.1371\/journal.pone.0270908","journal-title":"PLoS ONE"},{"issue":"4","key":"12234_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","volume":"21","author":"A Ardebili","year":"2023","unstructured":"Ardebili A, Izanloo A, Rastegar M (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev anti-infective therapy 21(4):387\u2013429. https:\/\/doi.org\/10.1080\/14787210.2023.2184346","journal-title":"Expert Rev anti-infective therapy"},{"issue":"4","key":"12234_CR71","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","volume":"21","author":"A Ardebili","year":"2023","unstructured":"Ardebili A, Izanloo A, Rastegar M (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev anti-infective therapy 21(4):387\u2013429. https:\/\/doi.org\/10.1080\/14787210.2023.2184346","journal-title":"Expert Rev anti-infective therapy"},{"issue":"1","key":"12234_CR72","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12879-025-10781-1","volume":"25","author":"MJ Alwazzeh","year":"2025","unstructured":"Alwazzeh MJ, Algazaq J, Al-Salem FA, Alabkari F, Alwarthan SM, Alhajri M, AlShehail BM, Alnimr A, Alrefaai AW, Alsaihati FH, Almuhanna FA (2025) Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients. BMC Infect Dis 25(1):416. https:\/\/doi.org\/10.1186\/s12879-025-10781-1","journal-title":"BMC Infect Dis"},{"key":"12234_CR73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jhin.2025.10.019","volume":"167","author":"ME Falagas","year":"2026","unstructured":"Falagas ME, Kontogiannis DS, Sargianou M, Bousi SE, Ntourakis D (2026) Colistin monotherapy versus colistin combination therapy in the treatment of patients with multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a meta-analysis. J Hosp Infect 167:211\u2013231. https:\/\/doi.org\/10.1016\/j.jhin.2025.10.019","journal-title":"J Hosp Infect"},{"issue":"9","key":"12234_CR74","doi-asserted-by":"publisher","first-page":"e0264620","DOI":"10.1128\/AAC.02646-20","volume":"65","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Nguyen L, Maassen PT, Stamper KC, Kebriaei R, Kaye KS, Castanheira M, Rybak MJ (2021) Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 65(9):e0264620. https:\/\/doi.org\/10.1128\/AAC.02646-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"12234_CR75","doi-asserted-by":"publisher","first-page":"178","DOI":"10.7883\/yoken.JJID.2023.364","volume":"77","author":"Y Kimura","year":"2024","unstructured":"Kimura Y, Hatayama N, Sato Y, Nishida S, Yoshino Y (2024) Efficacy of Cefiderocol, a Novel Siderophore Cephalosporin, against Multidrug Resistant Acinetobacter baumannii Clinical Isolates in Japan. Jpn J Infect Dis 77(3):178\u2013181. https:\/\/doi.org\/10.7883\/yoken.JJID.2023.364","journal-title":"Jpn J Infect Dis"},{"issue":"11","key":"12234_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112532","volume":"12","author":"B Yousefi","year":"2024","unstructured":"Yousefi B, Kashanipoor S, Mazaheri P, Alibabaei F, Babaeizad A, Asli S, Mohammadi S, Gorgin AH, Alipour T, Oksenych V, Eslami M (2024) Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance. Biomedicines 12(11):2532. https:\/\/doi.org\/10.3390\/biomedicines12112532","journal-title":"Biomedicines"},{"issue":"3","key":"12234_CR77","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00279-24","volume":"38","author":"V Dubey","year":"2025","unstructured":"Dubey V, Reza N, Hope W (2025) Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. Clinical microbiology reviews 38(3):e0027924. https:\/\/doi.org\/10.1128\/cmr.00279-24","journal-title":"Clinical microbiology reviews"},{"issue":"6","key":"12234_CR78","doi-asserted-by":"publisher","first-page":"e220124225835","DOI":"10.2174\/0118715265276432231217192054","volume":"24","author":"H Velmurugan","year":"2024","unstructured":"Velmurugan H, Venkatesan S, Meles HN, Neelambaram K, Thangaraju P (2024) Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review. Infectious disorders drug targets 24(6):e220124225835. https:\/\/doi.org\/10.2174\/0118715265276432231217192054","journal-title":"Infectious disorders drug targets"},{"issue":"9","key":"12234_CR79","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O\u2019Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D (2023) Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). The Lancet. Infectious diseases 23(9):1072\u20131084. https:\/\/doi.org\/10.1016\/S1473-3099(23)00184-6","journal-title":"The Lancet. Infectious diseases"},{"issue":"1","key":"12234_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics15010002","volume":"15","author":"IA Stoian","year":"2025","unstructured":"Stoian IA, Balas Maftei B, Florea CE, Rotaru A, Costin CA, Pasare MA, Crisan Dabija R, Manciuc C (2025) Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention-A Narrative Review. Antibiotics 15(1):2. https:\/\/doi.org\/10.3390\/antibiotics15010002","journal-title":"Antibiotics"},{"issue":"5","key":"12234_CR81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/antibiotics15050499","volume":"15","author":"S Viscardi","year":"2026","unstructured":"Viscardi S, Lipska P, Niezg\u00f3dka P, Duda-Madej A (2026) Sulbactam-Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii: A Narrative Review. Antibiot (Basel Switzerland) 15(5):499. https:\/\/doi.org\/10.3390\/antibiotics15050499","journal-title":"Antibiot (Basel Switzerland)"},{"issue":"4","key":"12234_CR82","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4103\/0255-0857.103767","volume":"30","author":"F \u015eim\u015fek","year":"2012","unstructured":"\u015eim\u015fek F, Gedik H, Y\u0131ld\u0131rmak MT, \u0130ris NE, T\u00fcrkmen A, Ersoy A, Ers\u00f6z M, G\u00fcc\u00fcyener A (2012) Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian Journal of Medical Microbiology 30(4):448\u2013452. https:\/\/doi.org\/10.4103\/0255-0857.103767","journal-title":"Indian Journal of Medical Microbiology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12234-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12234-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:34:57Z","timestamp":1782563697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12234-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12234"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12234-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors \u2013 none to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1020"}}